| 27.05 08:34 | dpa-AFX: AZN:Datopotamab Deruxtecan Shows Favorable Survival Results, Falls Short Of Statistical Significance |
| 29.04 08:30 | dpa-AFX: AstraZeneca: Enhertu Improved PFS In HR-positive, HER2-low Metastatic Breast Cancer |
| 10.04 07:15 | dpa-AFX: Roche Gets CE Mark For First Companion Diagnostic To Identify HER2-low Metastatic Breast Cancer |
| 06.04 04:02 | dpa-AFX: FDA Approves AstraZeneca And Daiichi Sankyo's Enhertu For Solid Tumors Treatment |
| 02.04 08:04 | dpa-AFX: *ASTRAZENECA AND DAIICHI SANKYO: FDA ACCEPTS DATOPOTAMAB DERUXTECAN BLA FOR BREAST CANCER |
| 04.03 08:41 | EU gibt Astrazeneca zwei Zulassungen für neues Krebsmedikament |
| 04.03 08:17 | dpa-AFX: *ASTRAZENECA AND DAIICHI SANKYO: EMA VALIDATES TWO MAAS FOR DATO-DXD IN TWO TYPES |
| 29.01 14:01 | dpa-AFX: AstraZeneca: FDA Grants ENHERTU Priority Review For Metastatic HER2-Positive Solid Tumors |
| 29.01 13:15 | dpa-AFX: *ASTRAZENECA : ENHERTU RECEIVES PRIORITY REVIEW IN U.S. FOR METASTATIC HER2-POSITIVE SOLID TUMORS |
| 17.01 07:38 | dpa-AFX: US Patent Office Invalidates Seagen Patent In Daiichi Sankyo Dispute |
| 17.01 07:20 | dpa-AFX: *U.S. PATENT OFFICE INVALIDATES SEAGEN PATENT IN DAIICHI SANKYO DISPUTE |
| 03.01 13:49 | dpa-AFX: Esperion Therapeutics, Daiichi Sankyo Europe Ink $125 Mln Amendment To Their Collaboration |
| 03.01 13:25 | dpa-AFX: *ESPERION THERAPEUTICS, DAIICHI SANKYO EUROPE ANNOUNCE $125 MLN AMENDMENT TO THEIR COLLABORATION |
| 22.12 14:48 | dpa-AFX: Merck, Daiichi Sankyo Say FDA Grants Priority Review In U.S. For Patritumab Deruxtecan |
| 23.10 17:15 | dpa-AFX: AZN : Enhertu Shows Survival Across Multiple HER2-Expressing Advanced Solid Tumors In Phase II Trial |
| 23.10 16:49 | dpa-AFX: AstraZeneca : Phase III Trial Of Datopotamab Deruxtecan In Breast Cancer Shows Improvement In PFS |
| 23.10 08:49 | dpa-AFX: AstraZeneca : Enhertu Approved In EU For Advanced Non-small Cell Lung Cancer Treatment |
| 23.10 08:33 | EU erlaubt Astrazeneca-Arznei Enhertu zur Behandlung von Lungenkrebs |
| 20.10 09:35 | MÄRKTE ASIEN/Schwach - Daiichi Sankyo haussieren mit Merck-Kooperation |
| 20.10 07:24 | dpa-AFX: Daiichi Sankyo, Merck Reach $22 Bln Worth Agreement On Antibody Drug Conjugate Candidates |
|
|
